Plant Comparison

Midland Hawthorn vs Red Clover

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant AMidland HawthornCrataegus laevigataRosaceaeFull monograph →
Plant BRed CloverTrifolium pratenseFabaceaeFull monograph →

At a glance

Midland Hawthorn and Red Clover: they share 6 indicated uses (arthritis / joint pain, cardiovascular / heart health, inflammation (general), …); 3 pharmacological actions in common.

Midland HawthornRed Clover
Constituents22
Pharmacological actions410
Indicated uses716
Safety notes22
Cited sources2244
Indicated uses
Only Midland Hawthorn
Insomnia / sleeplessness
Shared (6)
Arthritis / joint painCardiovascular / heart healthInflammation (general)Menstrual crampsMuscle spasmSkin irritation
Only Red Clover
BronchitisCoughRespiratory supportMenopauseHot flashesHigh cholesterolCancer (anticancer research)Blood sugar / diabetes supportCognitive functionWounds
Pharmacological actions
Only Midland Hawthorn
Sedative / sleep support
Shared (3)
Anti-inflammatoryAntioxidantAntispasmodic
Only Red Clover
ExpectorantLipid-loweringAnticancer (preclinical)Neuroprotective / cognition supportAntidiabetic (blood-sugar lowering)AntimicrobialVulnerary (wound healing)

Evidence face-off — shared uses

ConditionMidland HawthornRed CloverVerdict
Arthritis / joint pain1/105/10Stronger for Red Clover
Cardiovascular / heart health1/109/10Stronger for Red Clover
Inflammation (general)1/105/10Stronger for Red Clover
Menstrual cramps1/105/10Stronger for Red Clover
Muscle spasm1/105/10Stronger for Red Clover
Skin irritation1/105/10Stronger for Red Clover

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Oligomeric proanthocyanidins and flavonoids[5]

The principal cardioactive and antioxidant constituents, the basis for extract standardisation.

ProanthocyanidinsFlavonoidsQuercetin
Phenolic acids

Additional antioxidant constituents of the flower, leaf and fruit.

Phenolic acidsChlorogenic acid
Isoflavones (formononetin, biochanin A, daidzein, genistein)[14]

Phytoestrogenic isoflavones responsible for the plant's estrogenic and cardiovascular research interest; one of the richest known plant sources.

Flavonoids
Coumarins[40]

Contribute mild anticoagulant activity; relevant to the plant's caution around blood-thinning medication.

Coumarins

Pharmacological Actions

Anti-inflammatory[9, 15, 16]
Antioxidant[2, 5, 6, 7, 8, 9, 15, 16]
Antispasmodic[2, 10, 11, 15, 16]

Antispasmodic (cramp easing)

Sedative / sleep support[12, 15, 16]
Anti-inflammatory[4, 14, 17, 22, 28, 33, 34, 40, 41]
Antioxidant[4, 6, 14, 16, 17, 22, 28, 29, 40, 41]
Antispasmodic[8, 14, 40, 41]

Antispasmodic (cramp easing)

Expectorant[14, 40, 41]
Lipid-lowering[5, 11, 13]
Anticancer (preclinical)[16, 18, 19, 20, 21, 35, 36, 37]
Neuroprotective / cognition support[23, 30, 31, 32]
Antidiabetic (blood-sugar lowering)[24, 25, 38]
Antimicrobial[17, 27]
Vulnerary (wound healing)[17, 39]

Traditional & Indicated Uses

Arthritis / joint pain[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Cardiovascular / heart health[15, 16]Traditional · 1/10
Evidence: 1
Label: Cardiovascular / heart health
Inflammation (general)[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16]Traditional · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Menstrual cramps[15, 16]Traditional · 1/10

inferred from antispasmodic action

Evidence: 1
Label: Menstrual cramps
Muscle spasm[15, 16]Traditional · 1/10

inferred from antispasmodic action

Evidence: 1
Label: Muscle spasm
Skin irritation[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Arthritis / joint pain[14, 34, 40, 41]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Arthritis / joint pain
Bronchitis[14, 40, 41]Moderate · 5/10

inferred from expectorant action

Evidence: 5
Label: Bronchitis
Cardiovascular / heart health[2, 10, 13, 14, 16, 33, 40, 41]Strong · 9/10
Evidence: 9
Label: Cardiovascular / heart health
Cough[14, 40, 41]Moderate · 5/10

inferred from expectorant action

Evidence: 5
Label: Cough
Inflammation (general)[14, 28, 40, 41]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Inflammation (general)
Menstrual cramps[8, 14, 40, 41]Moderate · 5/10
Evidence: 5
Label: Menstrual cramps
Muscle spasm[8, 14, 40, 41]Moderate · 5/10

inferred from antispasmodic action

Evidence: 5
Label: Muscle spasm
Respiratory support[14, 40, 41]Moderate · 5/10

inferred from expectorant action

Evidence: 5
Label: Respiratory support
Skin irritation[7, 14, 40, 41]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Skin irritation
Menopause[1, 5, 11, 12, 15]Strong · 9/10
Evidence: 9
Label: Menopause
Hot flashes[1, 5, 11, 12]Strong · 9/10
Evidence: 9
Label: Hot flashes
High cholesterol[5, 11, 13]Strong · 9/10
Evidence: 9
Label: High cholesterol
Cancer (anticancer research)[16, 18, 19, 20, 21, 35, 36, 37]Good · 7/10

inferred from anticancer action

Evidence: 7
Label: Cancer (anticancer research)
Blood sugar / diabetes support[24, 25, 38]Traditional · 2/10
Evidence: 2
Label: Blood sugar / diabetes support
Cognitive function[23, 30, 31, 32]Good · 8/10

inferred from neuroprotective action

Evidence: 8
Label: Cognitive function
Wounds[17, 39]Good · 7/10

inferred from vulnerary action

Evidence: 7
Label: Wounds

Safety, Cautions & Contraindications

Safety note[15, 16]Caution

Generally safe and well tolerated. High doses may cause low blood pressure and sedation. May interact with cardiac glycosides (digoxin) and antihypertensive drugs. Consult a physician before using with existing heart medications.

Safety note[15, 16, 17]Info

Duke (2002) rates hawthorn (Crataegus spp., including C. laevigata) as a triple-plus herb (+++) with Commission E approval (score 2-3) for decreasing cardiac output in functional Stage II heart insufficiency (NYHA). Clinical evidence supports hawthorn standardized extracts (80-500 mg, standardized to flavonoids or procyanidins) for angina, arrhythmia, atherosclerosis, and hypertension. Hawthorn may potentiate digitalis and other cardiac medications and is not considered suitable for self-medication without professional guidance (Duke, 2002).

Safety note[14, 40, 41]Caution

Generally safe in normal dietary amounts. Isoflavones are phytoestrogens — exercise caution in oestrogen-receptor-positive breast cancer patients or those taking hormone therapies. May interact with warfarin (antiplatelet activity). Avoid in pregnancy and breastfeeding. Well tolerated in most adults.

Safety note[14, 40, 41, 42]Caution

Duke (2002) rates red clover as +++ and provides clinical evidence (score 2) for estrogenic activity — the plant is one of the richest plant sources of isoflavones (formononetin, biochanin A, daidzein, genistein). Clinical applications include menopausal symptom relief, osteoporosis prevention, and cardiovascular protection in peri-menopausal women. Dose: standardized extract providing 40–160 mg isoflavones daily. Duke cautions that due to strong estrogenic activity, red clover is not recommended in estrogen-dependent cancers (breast, uterine) or alongside hormone replacement therapy without medical supervision. Anti-coagulant coumarins are also present (Duke, 2002).

External Ids

Gbif: 8252683
Wikidata: Q159553
Gbif: 8324121
Wikidata: Q156635

Botanical Description

Small deciduous tree or large shrub with thorny branches and glossy, shallowly lobed leaves (less deeply cut than common hawthorn). Clusters of small, five-petalled white (occasionally pink) flowers with a strong scent appear in spring, followed by small red berries (haws), each usually containing two seeds (nutlets).[1]

Height: 4-8 m
Habit: Small deciduous, thorny tree or large shrub
Leaves: Glossy, shallowly lobed (less deeply cut than C. monogyna)
Flowers: Clusters of small, five-petalled white to pink, strongly scented flowers
Stem: Thorny branches; grey, fissured bark on older wood
Root: Deep, spreading root system
Fruit: Small red berry (haw), usually with two seeds
Flowering Period: April-May

Short-lived perennial herb with trifoliate leaves, each leaflet oval and often marked with a pale chevron, arising from a spreading, slightly hairy stem. Dense, rounded, pink to magenta flower heads are borne at the stem tips.[40]

Height: 20-60 cm
Habit: Short-lived perennial herb, spreading via a branching taproot
Leaves: Trifoliate, each leaflet oval with a pale chevron marking, slightly hairy
Flowers: Dense, rounded heads of small pink to magenta pea-like flowers
Stem: Slightly hairy, branching, spreading
Root: Branching taproot with nitrogen-fixing root nodules
Fruit: Small pod containing 1-2 seeds, enclosed within the dried flower head
Flowering Period: May-September

Habitat

Grows in woodland, woodland edges, hedgerows and scrub, typically on richer, damper soils than common hawthorn; native to western and central Europe.[1]

Grows in meadows, pastures, roadsides and grassy waste ground; native to Europe, western Asia and North Africa and widely naturalised and cultivated as a forage crop elsewhere.[40]

Harvesting

Flowers are picked as they open in spring, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn; all three parts are used, often combined, in hawthorn preparations.[1]

Parts: Flower, Fruit, Leaf
Season: Flower and leaf in spring; fruit in autumn

The flowering heads are picked at full bloom in summer and dried quickly in a warm, shaded, airy place to preserve isoflavone content and colour.[40]

Parts: Flower, Leaf
Season: Summer, at full bloom

Traditional Uses

Hawthorn flower, leaf and berry have a long European tradition, and substantial modern clinical study, as a cardiovascular tonic - supporting heart function, mild circulatory complaints and calming nervous tension - reflected in its traditional use for 'heart strengthening' and its modern standing as a well-studied botanical for mild heart failure symptoms.[1]

Red clover flower has a long folk tradition as a blood-purifying and expectorant remedy for coughs and skin complaints, and more recently has become one of the most studied herbal sources of isoflavone phytoestrogens, researched for menopausal symptom relief and cardiovascular and bone support.[14, 40, 41]

Preparations

Standardised extract[1]

Leaf-and-flower extract standardised to flavonoid or oligomeric proanthocyanidin content, taken as tablets or capsules; the best-studied clinical form.

Infusion (flower)[40]

Dried flower heads infused in hot water as a traditional tea for coughs and as a general tonic.

Standardized isoflavone extract[14]

Standardized isoflavone extract in tablet form, the form used in most menopause-related clinical research.

Dosage

Standardised extract[14]

The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.

Herbal tea[14]

The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.

Standardized extract[14]

Clinical research commonly uses around 40-80 mg isoflavones daily. Educational reference only, not a prescription.

References

REF-0782, REF-0783, REF-0784, REF-1779, REF-1780, REF-1781, REF-1782, REF-1783, REF-1784, REF-1785, REF-1786, REF-1787, REF-1788
REF-1104, REF-1105, REF-1106, REF-1107, REF-1108, REF-1109, REF-1110, REF-1111, REF-1112, REF-1113, REF-2344, REF-2345, REF-2346, REF-0013, REF-2347, REF-2889, REF-2890, REF-2891, REF-2892, REF-2893, REF-2894, REF-2895, REF-2896, REF-2897, REF-2898, REF-2899, REF-2900, REF-2923, REF-2924, REF-2925, REF-2926, REF-2927, REF-2928, REF-2929, REF-2930, REF-2931, REF-2932, REF-2933, REF-2934

Drug Class Interactions

Safety note[18, 19, 20]Caution
Drug Class: cardiac-glycosides
Mechanism: Hawthorn has its own positive effect on the heart (a Cochrane review found it improves heart-failure symptoms and exercise tolerance) and shares P-glycoprotein handling with digoxin, so combining it with digoxin or other cardiac-glycoside heart drugs should be supervised even though a controlled study found no major change in digoxin levels.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[19, 20]Caution
Drug Class: antihypertensives
Mechanism: Hawthorn can mildly lower blood pressure and reduce cardiac oxygen demand (a Cochrane meta-analysis found a lower pressure-heart-rate product), which may add to the effect of blood-pressure and heart-failure medicines.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[21, 22]Caution
Drug Class: sedatives-cns-depressants
Mechanism: Hawthorn is traditionally used as a calming, sedative herb; taken with sedatives, sleeping tablets or other central-nervous-system depressants (including alcohol) it may add to drowsiness and slowed reactions.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[43, 44]Caution
Drug Class: hormonal-therapies
Mechanism: Red clover is rich in isoflavones that act like weak oestrogens; its safety alongside hormone medicines (such as the contraceptive pill, HRT, or breast-cancer hormone treatments like tamoxifen) or in hormone-sensitive conditions is not established, so combined use warrants caution and medical advice.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Fong, H.H.S. and Bauman, J.L (2002) 'Hawthorn', Journal of Cardiovascular Nursing, 16(4), pp. 1-8. doi:10.1097/00005082-200207000-00002 Traditional / reference
    https://doi.org/10.1097/00005082-200207000-00002
  2. Orhan, I.E (2018) 'Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb', Current Medicinal Chemistry, 25(37), pp. 4854-4865. doi:10.2174/0929867323666160919095519 Traditional / reference
    https://doi.org/10.2174/0929867323666160919095519
  3. Ahmadipour, B., Kalantar, M., Abaszadeh, S. and Hassanpour, H (2024) 'Antioxidant and antihyperlipidemic effects of hawthorn extract (Crataegus oxyacantha) in broiler chickens', Veterinary Medicine and Science, 10(3), pp. e1414. doi:10.1002/vms3.1414 Preclinical
    https://doi.org/10.1002/vms3.1414
  4. Rigelsky, J.M. and Sweet, B.V (2002) 'Hawthorn: pharmacology and therapeutic uses', American Journal of Health-System Pharmacy, 59(5), pp. 417-422. doi:10.1093/ajhp/59.5.417 Meta-analysis / review
    https://doi.org/10.1093/ajhp/59.5.417
  5. Saeedi, G., Jeivad, F., Goharbari, M., Gheshlaghi, G.H. and Sabzevari, O (2018) 'Ethanol Extract of Crataegus Oxyacantha L. Ameliorate Dietary Non-Alcoholic Fatty Liver Disease in Rat', Drug Research, 68(10), pp. 553-559. doi:10.1055/a-0579-7532 Preclinical
    https://doi.org/10.1055/a-0579-7532
  6. Mecheri, A., Benabderrahmane, W., Amrani, A., Boubekri, N., Benayache, F., Benayache, S. and Zama, D (2019) 'Hepatoprotective Effects of Algerian Crataegus oxyacantha Leaves', Recent Patents on Food, Nutrition & Agriculture, 10(1), pp. 70-75. doi:10.2174/2212798410666180730095456 Preclinical
    https://doi.org/10.2174/2212798410666180730095456
  7. Benabderrahmane, W., Lores, M., Benaissa, O., Lamas, J.P., de Miguel, T., Amrani, A., Benayache, F. and Benayache, S (2019) 'Polyphenolic content and bioactivities of Crataegus oxyacantha L. (Rosaceae)', Natural Product Research, 35(4), pp. 627-632. doi:10.1080/14786419.2019.1582044 Preclinical
    https://doi.org/10.1080/14786419.2019.1582044
  8. Ali, M., Muhammad, S., Shah, M.R., Khan, A., Rashid, U., Farooq, U., Ullah, F., Sadiq, A., Ayaz, M., Ali, M., Ahmad, M. and Latif, A (2017) 'Neurologically Potent Molecules from Crataegus oxyacantha; Isolation, Anticholinesterase Inhibition, and Molecular Docking', Frontiers in Pharmacology, 8, pp. 327. doi:10.3389/fphar.2017.00327 Preclinical
    https://doi.org/10.3389/fphar.2017.00327
  9. Cuevas-Duran, R.E., Medrano-Rodriguez, J.C., Sanchez-Aguilar, M., Soria-Castro, E., Rubio-Ruiz, M.E., Del Valle-Mondragon, L., Sanchez-Mendoza, A., Torres-Narvaez, J.C., Pastelin-Hernandez, G. and Ibarra-Lara, L (2017) 'Extracts of Crataegus oxyacantha and Rosmarinus officinalis Attenuate Ischemic Myocardial Damage by Decreasing Oxidative Stress and Regulating the Production of Cardiac Vasoactive Agents', International Journal of Molecular Sciences, 18(11), pp. 2412. doi:10.3390/ijms18112412 Preclinical
    https://doi.org/10.3390/ijms18112412
  10. Alp, H., Soner, B.C., Baysal, T. and Sahin, A.S (2014) 'Protective effects of Hawthorn (Crataegus oxyacantha) extract against digoxin-induced arrhythmias in rats', Anatolian Journal of Cardiology, 15(12), pp. 970-975. doi:10.5152/akd.2014.5869 Preclinical
    https://doi.org/10.5152/akd.2014.5869
  11. Rothfuss, M.A., Pascht, U. and Kissling, G (2001) 'Effect of long-term application of Crataegus oxyacantha on ischemia and reperfusion induced arrhythmias in rats', Arzneimittel-Forschung, 51(1), pp. 24-28. doi:10.1055/s-0031-1299998 Preclinical
    https://doi.org/10.1055/s-0031-1299998
  12. Khan, A., Akram, M., Thiruvengadam, M., Daniyal, M., Zakki, S.A., Munir, N., Zainab, R., Heydari, M., Mosavat, S.H., Rebezov, M. and Shariati, M.A (2022) 'Anti-anxiety Properties of Selected Medicinal Plants', Current Pharmaceutical Biotechnology, 23(8), pp. 1041-1060. doi:10.2174/1389201022666210122125131 Meta-analysis / review
    https://doi.org/10.2174/1389201022666210122125131
  13. Rastogi, S., Pandey, M.M. and Rawat, A.K.S (2015) 'Traditional herbs: a remedy for cardiovascular disorders', Phytomedicine, 23(11), pp. 1082-1089. doi:10.1016/j.phymed.2015.10.012 Meta-analysis / review
    https://doi.org/10.1016/j.phymed.2015.10.012
  14. European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
    https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore
  15. Hendel, N. and Hendel, M (2014) 'Hedgerow Medicine'. Traditional / reference
    https://scholar.google.com/scholar?q=Hedgerow%20Medicine
  16. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
    https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  18. Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
    https://doi.org/10.1177/0091270003253417
  19. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD005312.pub2
  20. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD005312.pub2
  21. Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
    https://doi.org/10.1002/ptr.8201
  22. Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
    https://doi.org/10.1177/1534735404265003
  1. Kanadys, W., Baranska, A., Blaszczuk, A., Polz-Dacewicz, M. and others (2021) 'Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials', Nutrients, 13(4), pp. 1258. doi:10.3390/nu13041258 Meta-analysis / review
    https://doi.org/10.3390/nu13041258
  2. Kanadys, W., Baranska, A., Jedrych, M., Religioni, U. and others (2019) 'Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of perimenopausal and postmenopausal women-A systematic review and meta-analysis', Maturitas, 132, pp. 7-16. doi:10.1016/j.maturitas.2019.11.001 Meta-analysis / review
    https://doi.org/10.1016/j.maturitas.2019.11.001
  3. Yokoyama, S.I., Kodera, M., Hirai, A., Nakada, M. and others (2020) 'Red Clover (Trifolium pratense L.) Sprout Prevents Metabolic Syndrome', Journal of Nutritional Science and Vitaminology, 66(1), pp. 48-53. doi:10.3177/jnsv.66.48 Preclinical
    https://doi.org/10.3177/jnsv.66.48
  4. Gosciniak, A., Szulc, P., Zielewicz, W., Walkowiak, J. and others (2023) 'Multidirectional Effects of Red Clover (Trifolium pratense L.) in Support of Menopause Therapy', Molecules, 28(13), pp. 5178. doi:10.3390/molecules28135178 Meta-analysis / review
    https://doi.org/10.3390/molecules28135178
  5. Booth, N.L., Piersen, C.E., Banuvar, S., Geller, S.E. and others (2006) 'Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review', Menopause, 13(2), pp. 251-264. doi:10.1097/01.gme.0000198297.40269.f7 Meta-analysis / review
    https://doi.org/10.1097/01.gme.0000198297.40269.f7
  6. Oza, M.J. and Kulkarni, Y.A (2020) 'Trifolium pratense (Red Clover) Improves SIRT1 Expression and Glycogen Content in High Fat Diet-Streptozotocin Induced Type 2 Diabetes in Rats', Chemistry & Biodiversity, 17(4), pp. e2000019. doi:10.1002/cbdv.202000019 Preclinical
    https://doi.org/10.1002/cbdv.202000019
  7. Circosta, C., De Pasquale, R., Palumbo, D.R., Samperi, S. and others (2006) 'Effects of isoflavones from red clover (Trifolium pratense) on skin changes induced by ovariectomy in rats', Phytotherapy Research, 20(12), pp. 1096-1099. doi:10.1002/ptr.2017 Preclinical
    https://doi.org/10.1002/ptr.2017
  8. Brandli, A., Simpson, J.S. and Ventura, S (2010) 'Isoflavones isolated from red clover (Trifolium pratense) inhibit smooth muscle contraction of the isolated rat prostate gland', Phytomedicine, 17(11), pp. 895-901. doi:10.1016/j.phymed.2010.05.006 Preclinical
    https://doi.org/10.1016/j.phymed.2010.05.006
  9. Burdette, J.E., Liu, J., Lantvit, D., Lim, E. and others (2002) 'Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Sprague-Dawley rats', The Journal of Nutrition, 132(1), pp. 27-30. doi:10.1093/jn/132.1.27 Preclinical
    https://doi.org/10.1093/jn/132.1.27
  10. Jiang, Y.B. and Yang, Y.R (2016) 'Trifolium pratense isoflavones improve pulmonary vascular remodelling in broiler chickens', Journal of Animal Physiology and Animal Nutrition, 100(6), pp. 1159-1168. doi:10.1111/jpn.12424 Preclinical
    https://doi.org/10.1111/jpn.12424
  11. Yigit, E. and Unsal, S (2024) 'Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial', Climacteric, 27(6), pp. 548-554. doi:10.1080/13697137.2024.2393121 Randomized trial
    https://doi.org/10.1080/13697137.2024.2393121
  12. Lethaby, A.E., Brown, J., Marjoribanks, J., Kronenberg, F., Roberts, H. and Eden, J (2007) 'Phytoestrogens for vasomotor menopausal symptoms', Cochrane Database of Systematic Reviews, (4), pp. CD001395. doi:10.1002/14651858.CD001395.pub3 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD001395.pub3
  13. Geller, S.E. and Studee, L (2006) 'Soy and red clover for mid-life and aging', Climacteric, 9(4), pp. 245-263. doi:10.1080/13697130600736934 Meta-analysis / review
    https://doi.org/10.1080/13697130600736934
  14. Atkinson, C. et al (2004) 'The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial', 79(2), pp. 326--333. doi:10.1093/ajcn/79.2.326 Randomized trial
    https://doi.org/10.1093/ajcn/79.2.326
  15. Quah, Y., Yi-Le, J.C., Park, N.H., Lee, Y.Y., Lee, E.B., Jang, S.H., Kim, M.J., Rhee, M.H., Lee, S.J. and Park, S.C (2022) 'Serum biomarker-based osteoporosis risk prediction and the systemic effects of Trifolium pratense ethanolic extract in a postmenopausal model', Chinese Medicine, 17(1), pp. 70. doi:10.1186/s13020-022-00622-7 Preclinical
    https://doi.org/10.1186/s13020-022-00622-7
  16. Mohsen, A. and Fatemeh, K. and Leila, N. and Mona, P. and Mohammad, Z. and Mozafar, K (2021) 'Pharmacological and therapeutic properties of the Red Clover (Trifolium pratense L.): an overview of the new finding', J Tradit Chin Med, 41(4), pp. 642-649. doi:10.19852/j.cnki.jtcm.20210324.001 Meta-analysis / review
    https://doi.org/10.19852/j.cnki.jtcm.20210324.001
  17. Antonescu Mintas, A.I. and Miere Groza, F. and Fritea, L. and Ganea, M. and Zdrinca, M. and Dobjanschi, L. and Antonescu, A. and Vicas, S.I. and Bodog, F. and Sindhu, R.K. and Cavalu, S (2021) 'Perspectives on the Combined Effects of Trifolium pratense and Ocimum basilicum Extracts in Terms of Phytochemical Profile and Pharmacological Effects', Plants (Basel), 10(7). doi:10.3390/plants10071390 Meta-analysis / review
    https://doi.org/10.3390/plants10071390
  18. Tanrıverdi, G. and Abdulova, A. and Çölgeçen, H. and Atar, H. and Kaleci, B. and Ekiz-Yılmaz, T (2023) 'Investigation of apoptotic and antiproliferative effects of Turkish natural tetraploid Trifolium pratense L. extract on C6 glioblastoma cells via light and electron microscopy', Ultrastruct Pathol, 47(3), pp. 160-171. doi:10.1080/01913123.2023.2184893 Preclinical
    https://doi.org/10.1080/01913123.2023.2184893
  19. Zakłos-Szyda, M. and Budryn, G (2020) 'The Effects of Trifolium pratense L. Sprouts' Phenolic Compounds on Cell Growth and Migration of MDA-MB-231, MCF-7 and HUVEC Cells', Nutrients, 12(1). doi:10.3390/nu12010257 Preclinical
    https://doi.org/10.3390/nu12010257
  20. Khazayel, S. and Faraji, M.H. and Akbaribazm, M. and Khazaei, M. and Niromand, E. and Khazaei, M.R (2025) 'Synergistic inhibitory effects of Trifolium pratense L. extract and doxorubicin on 4T1 tumor-bearing mice are mediated via targeting the Wnt/beta-catenin pathway and reversal of epithelial-mesenchymal transition', Avicenna J Phytomed, 15(5), pp. 1546-1561. doi:10.22038/ajp.2025.25940 Preclinical
    https://doi.org/10.22038/ajp.2025.25940
  21. Shirani Asl, V. and Rafieemehr, H. and Tamaddon, G (2024) 'The impact of Trifolium pratense extract on apoptosis and autophagy in NALM-6 cells: implications for B-ALL intervention', Med Oncol, 41(11), pp. 257. doi:10.1007/s12032-024-02485-4 Preclinical
    https://doi.org/10.1007/s12032-024-02485-4
  22. Won, J.P. and Kim, E. and Hur, J. and Lee, H.G. and Lee, W.J. and Seo, H.G (2023) 'Red clover (Trifolium pratense L.) extract inhibits ferroptotic cell death by modulating cellular iron homeostasis', J Ethnopharmacol, 308, pp. 116267. doi:10.1016/j.jep.2023.116267 Preclinical
    https://doi.org/10.1016/j.jep.2023.116267
  23. Al-Shami, A.S. and Essawy, A.E. and Elkader, H.A.E.A (2023) 'Molecular mechanisms underlying the potential neuroprotective effects of Trifolium pratense and its phytoestrogen-isoflavones in neurodegenerative disorders', Phytother Res, 37(6), pp. 2693-2737. doi:10.1002/ptr.7870 Meta-analysis / review
    https://doi.org/10.1002/ptr.7870
  24. Zhang, H. and Zhao, J. and Shang, H. and Guo, Y. and Chen, S (2020) 'Extraction, purification, hypoglycemic and antioxidant activities of red clover (Trifolium pratense L.) polysaccharides', Int J Biol Macromol, 148, pp. 750-760. doi:10.1016/j.ijbiomac.2020.01.194 Preclinical
    https://doi.org/10.1016/j.ijbiomac.2020.01.194
  25. Khazaei, A.H. and Bozorgi, A. and Ghanbari, E. and Bozorgi, M. and Khazaei, M (2025) 'Trifolium pratense-Derived Exosome Improved Serum Biochemical Parameters and Pancreatic Genes in STZ-Induced Diabetic Rats', Endocrinol Diabetes Metab, 8(5), pp. e70103. doi:10.1002/edm2.70103 Preclinical
    https://doi.org/10.1002/edm2.70103
  26. Hitzman, R. and Malca-Garcia, G.R. and Howell, C. and Park, H.Y. and Friesen, J.B. and Dong, H. and Dunlap, T. and McAlpine, J.B. and Vollmer, G. and Bosland, M.C. and Nikolić, D. and Lankin, D.C. and Chen, S.N. and Bolton, J.L. and Pauli, G.F. and Dietz, B.M (2023) 'DESIGNER fraction concept unmasks minor bioactive constituents in red clover (Trifolium pratense L.)', Phytochemistry, 214, pp. 113789. doi:10.1016/j.phytochem.2023.113789 Preclinical
    https://doi.org/10.1016/j.phytochem.2023.113789
  27. Lien, Y.Y. and Shyur, L.F. and Cheng, Y.B. and Chang, M.T. and Chang, C.T. and Chen, Y.H. and Lai, G.H. and Liao, H.Y. and Cheng, M.C (2024) 'Trifolium pratense as a novel phytogenic supplement, is an anticoccidial agent in chickens', Poult Sci, 103(10), pp. 104064. doi:10.1016/j.psj.2024.104064 Preclinical
    https://doi.org/10.1016/j.psj.2024.104064
  28. Lee, S.G. and Brownmiller, C. and Lee, S. and Kang, H.W (2020) 'Anti-Inflammatory and Antioxidant Effects of Anthocyanins of Trifolium pratense (Red Clover) in Lipopolysaccharide-Stimulated RAW-267.4 Macrophages', Nutrients, 12(4), pp. 1089-1089. doi:10.3390/nu12041089 Preclinical
    https://doi.org/10.3390/nu12041089
  29. Akbaribazm, M. and Khazaei, M.R. and Khazaei, M.R. and Khazaei, M. and Khazaei, M (2020) 'Phytochemicals and antioxidant activity of alcoholic/hydroalcoholic extract of Trifolium pratense', Chinese Herbal Medicines, 12(3), pp. 326-335. doi:10.1016/j.chmed.2020.02.002 Preclinical
    https://doi.org/10.1016/j.chmed.2020.02.002
  30. Fu, X. and Qin, T. and Yu, J. and Jiao, J. and Ma, Z. and Fu, Q. and Deng, X. and Ma, S (2019) 'Formononetin Ameliorates Cognitive Disorder via PGC-1α Pathway in Neuroinflammation Conditions in High-Fat Diet-Induced Mice', CNS & Neurological Disorders - Drug Targets, 18(7), pp. 566-577. doi:10.2174/1871527318666190807160137 Preclinical
    https://doi.org/10.2174/1871527318666190807160137
  31. Singh, L. and Kaur, H. and Arya, G.C. and Bhatti, R (2023) 'Neuroprotective potential of formononetin, a naturally occurring isoflavone phytoestrogen', Chemical Biology & Drug Design, 103(1), pp. e14353-e14353. doi:10.1111/cbdd.14353 Meta-analysis / review
    https://doi.org/10.1111/cbdd.14353
  32. Tan, J.W. and Kim, M (2016) 'Neuroprotective Effects of Biochanin A against β-Amyloid-Induced Neurotoxicity in PC12 Cells via a Mitochondrial-Dependent Apoptosis Pathway', Molecules, 21(5), pp. 548-548. doi:10.3390/molecules21050548 Preclinical
    https://doi.org/10.3390/molecules21050548
  33. Bai, Y. and Li, Z. and Liu, W. and Gao, D. and Liu, M. and Zhang, P (2019) 'Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway', Acta Cirúrgica Brasileira, 34(11), pp. e201901104-e201901104. doi:10.1590/s0102-865020190110000004 Preclinical
    https://doi.org/10.1590/s0102-865020190110000004
  34. Félix, F.B. and Vago, J.P. and Fernandes, D.D.O. and Martins, D.G. and Zaidan, I. and Gonçalves, W.A. and Costa, W.C. and Araújo, J.M.D. and Queiroz‐Junior, C.M. and Campolina-Silva, G.H. and Soriani, F.M. and Sousa, L.P. and Grespan, R. and Teixeira, M.M. and Pinho, V (2021) 'Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism', Frontiers in Pharmacology, 12, pp. 662308-662308. doi:10.3389/fphar.2021.662308 Preclinical
    https://doi.org/10.3389/fphar.2021.662308
  35. Akbaribazm, M. and Khazaei, M.R. and Khazaei, M.R. and Khazaei, M. and Khazaei, M (2020) 'Trifolium pratense L. (red clover) extract and doxorubicin synergistically inhibits proliferation of 4T1 breast cancer in tumor‐bearing BALB/c mice through modulation of apoptosis and increase antioxidant and anti‐inflammatory related pathways', Food Science & Nutrition, 8(8), pp. 4276-4290. doi:10.1002/fsn3.1724 Preclinical
    https://doi.org/10.1002/fsn3.1724
  36. Akbaribazm, M. and Khazaei, M.R. and Khazaei, M.R. and Khazaei, F. and Khazaei, M. and Khazaei, M (2020) 'Doxorubicin and Trifolium pratense L. (Red clover) extract synergistically inhibits brain and lung metastases in 4T1 tumor‐bearing BALB/c mice', Food Science & Nutrition, 8(10), pp. 5557-5570. doi:10.1002/fsn3.1820 Preclinical
    https://doi.org/10.1002/fsn3.1820
  37. Khazaei, M. and Pazhouhi, M (2018) 'Antiproliferative Effect of Trifolium Pratens L. Extract in Human Breast Cancer Cells', Nutrition and Cancer, 71(1), pp. 128-140. doi:10.1080/01635581.2018.1521443 Preclinical
    https://doi.org/10.1080/01635581.2018.1521443
  38. Pazhouhi, M. and Khazaei, M (2018) 'Protective effect of hydroalcoholic extracts of Trifolium pratense L. on pancreatic β cell line (RIN-5F) against cytotoxicty of streptozotocin', Research in Pharmaceutical Sciences, 13(4), pp. 324-324. doi:10.4103/1735-5362.235159 Preclinical
    https://doi.org/10.4103/1735-5362.235159
  39. Antonescu, I.A. and Antonescu, A. and Miere, F. and Fritea, L. and Teușdea, A.C. and Vicaș, L.G. and Vicaş, S.I. and Brihan, I. and Domuța, M. and Zdrîncă, M. and Zdrîncă, M. and Cavalu, S (2021) 'Evaluation of Wound Healing Potential of Novel Hydrogel Based on Ocimum basilicum and Trifolium pratense Extracts', Processes, 9(11), pp. 2096-2096. doi:10.3390/pr9112096 Preclinical
    https://doi.org/10.3390/pr9112096
  40. British Herbal Medicine Association (1996) 'British Herbal Pharmacopoeia'. Traditional / reference
    https://scholar.google.com/scholar?q=British%20Herbal%20Pharmacopoeia
  41. Hoffmann, D (2003) 'Medical Herbalism'. Traditional / reference
    https://scholar.google.com/scholar?q=Medical%20Herbalism
  42. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  43. Booth, N.L., Piersen, C.E., Banuvar, S., Geller, S.E., Shulman, L.P. and Farnsworth, N.R (2006) 'Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review', Menopause, 13(2), pp. 251-264. doi:10.1097/01.gme.0000198297.40269.f7 Meta-analysis / review
    https://doi.org/10.1097/01.gme.0000198297.40269.f7
  44. Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., Kennedy, D., Cooley, K., Wong, R., Sagar, S., Sabri, E. and Fergusson, D (2013) 'Soy, red clover, and isoflavones and breast cancer: a systematic review', PLoS One, 8(11), pp. e81968. doi:10.1371/journal.pone.0081968 Meta-analysis / review
    https://doi.org/10.1371/journal.pone.0081968

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.